Strata Oncology, a precision oncology company, today announced an agreement with Epizyme to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with relapsed or refractory non-Hodgkins lymphoma (NHL).
Cerêve Inc., manufacturer of the Cerêve Insomnia Therapy for treating people with insomnia, today announced it has appointed Donald J. Spence President and Chief Executive Officer.
Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, both of which are open for enrollment.
Arboretum Ventures, a leading healthcare venture capital firm, today announced the promotion of Tom Shehab, M.D. to Managing Director. Dr. Shehab began his career at Arboretum in 2014 as a Principal after spending several years as a member of the Arboretum Technical Advisory Board.
Digital therapy could soon be prescribed and reimbursed like a pharmaceutical drug for patients with chronic substance use disorder. “This could be a watershed moment for digital health,” said Corey McCann, MD, PhD, chief executive officer of Pear Therapeutics, the developer of the software.
Cerêve Inc., a privately-held health care company preparing to launch its FDA-cleared insomnia device, announced today the closing of a $38 million Series B round of financing led by KKR, a leading global investment firm.
NxThera, Inc., a medical device company pioneering the application of its convective radio frequency water vapor thermal therapy platform technology to treat endourological conditions, today announced the in press publication of the 2-year data from the Rezūm II pivotal study in The Journal of Urology.
Strata Oncology today announced launch of the Strata Trial, a nationwide observational study providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, to study the impact of tumor sequencing on clinical trial enrollment.
Cardiac Dimensions, the leader in minimally invasive repair therapies for functional mitral regurgitation (FMR), today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the pivotal CARILLON trial.
ConcertoHealth®, the nation’s leading provider of healthcare services for complex, frail, elderly, and Medicare-Medicaid dual-eligible patients, today announced the completion of a $30 million round of financing from existing investors.
No more posts to load.
Load More Posts